News
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, today announced that it will release second-quarter 2024 financial results and provide a business update on August 7, 2024, after the market closes. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-only webcast
The listen-only webcast will be available on the company’s website at www.allogene.com on the Investors tab in the News & Events section. A replay will be available on the Company’s website for approximately 30 days.
Conference Call Recording
If you want the option to ask a question on the conference call, use this link to register. When you register for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, headquartered in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune diseases. Led by a management team with significant expertise in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available, on-demand cell therapy more reliably and at greater scale to more patients. For more information, visit www.allogene.comand follow Allogene Therapeutics on X (formerly Twitter) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations regarding, among other things, Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune diseases on demand, more reliably and at greater scale to more patients. A number of factors could cause Allogene’s expectations to differ materially from actual results, including risks and uncertainties related to our product candidates being based on new technologies, which make it difficult to predict the timing and cost of product candidate development, the safety or efficacy of a product candidate and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including, without limitation, under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Any forward-looking statements made in this press release speak only as of the date of this press release. Allogene undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
The story continues
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Contact Allogene Media/Investors:
Cristina Cassiano
EVP, Director of Corporate Affairs and Brand Strategy
Christine.Cassiano@allogene.com